What are GLP-1 receptor agonists and why are they now prominent in the RACGP T2D handbook?

GLP-1 receptor agonists — such as semaglutide (Ozempic for T2D, Wegovy for obesity) and tirzepatide (Mounjaro) — stimulate insulin release, suppress glucagon, reduce appetite, and slow gastric emptying. Beyond glucose management, several major cardiovascular outcomes trials have shown reductions in heart attack, stroke, and cardiovascular death in people with T2D and established cardiovascular disease. The updated RACGP handbook formally elevates GLP-1 RAs in the treatment algorithm for patients with T2D and cardiovascular disease, kidney disease, or obesity — recognising that these medicines do more than lower blood glucose.

Is tirzepatide (Mounjaro) available on the PBS in Australia?

No. The PBAC recommended tirzepatide for T2D at its March 2026 meeting, but Eli Lilly rejected the listing, stating the government price offer was unrealistic and lower than any comparable healthcare system. Tirzepatide is available on private prescription in Australia at approximately $350–500 per month depending on dose. A PBS listing for obesity management is considered even less likely following the failed T2D negotiations. Semaglutide (Ozempic) remains PBS-listed for T2D; semaglutide at the higher obesity dose (Wegovy) has a PBAC recommendation for obesity with established cardiovascular disease but has not yet been listed.

The RACGP refreshed its type 2 diabetes handbook — what changed for GPs

What just happened

The RACGP has released a refresh of its flagship Management of Type 2 Diabetes: A Handbook for General Practice — the first major update in roughly four years, during which the evidence base for managing T2D has shifted substantially. The most significant changes are around GLP-1 receptor agonists and SGLT2 inhibitors: medicines that were approved for glucose management but have since demonstrated cardiovascular and renal outcomes that put them in a different category from earlier diabetes drugs.

The timing lands awkwardly. The clinical evidence for these medicines is strong. The access picture in Australia is not.

The person reading this might have T2D, or be watching a family member manage it for years on the same combination of drugs without anyone revisiting the overall treatment strategy. Or she is at the pre-diabetes threshold and wondering what the landscape looks like. The honest picture is that the guideline has caught up to the evidence; the PBS has not yet fully caught up to the guideline.

The both-and

The clinical case for rethinking type 2 diabetes treatment is settled. The question of what is actually accessible in Australia is more complicated.

What the updated handbook now says

The RACGP handbook refresh includes new sections on the use of GLP-1 receptor agonists and SGLT2 inhibitors in people with T2D and established cardiovascular disease, heart failure, or chronic kidney disease. The framing is no longer primarily about glucose targets — it is about cardiorenal risk reduction.

This represents a meaningful evolution in how T2D is positioned in Australian general practice. For many years, the default framing was: control blood glucose (with HbA1c as the proxy), add other cardiovascular risk management alongside. The updated handbook now explicitly positions certain medicines — particularly SGLT2 inhibitors for people with heart failure or kidney disease, and GLP-1 RAs for people with cardiovascular disease — as the indicated choice based on their organ-protective evidence, not just their glucose-lowering properties.

Weight management has also been given more specific guidance. The handbook acknowledges that even modest weight loss of 5–10% provides clinical benefits in T2D — improved glycaemic management, blood pressure, and lipid profiles — particularly early in the disease. GLP-1 RAs are now discussed explicitly in this context.

The PBS access picture: where the science and the system diverge

Here is where the update runs into a friction point that is worth understanding clearly.

Semaglutide (Ozempic) is PBS-listed for T2D with inadequate glycaemic control. This is the route through which it’s subsidised for the indication the handbook now formally elevates.

Semaglutide at the obesity dose (Wegovy) is a different product at a higher dose. The PBAC recommended it for PBS listing for obesity with established cardiovascular disease at the November 2025 PBAC meeting, with a slow and managed rollout recommended to contain costs. That listing has not yet been finalised.

Tirzepatide (Mounjaro) — which the evidence suggests is more effective than semaglutide for both glucose management and weight — was recommended by the PBAC for T2D at its March 2026 meeting, but Eli Lilly rejected the listing. The manufacturer described the government’s price offer as “unrealistic and unviable” — lower than any comparable healthcare system globally, including China. The practical consequence: tirzepatide is available in Australia on private prescription at approximately $350–500 per month. For most patients, that is out of reach on a chronic basis.

The PBAC has been explicit that it intends to manage the GLP-1 rollout carefully — rationing access to the highest-risk groups first, managing the fiscal exposure of subsidising what could eventually become the most widely prescribed class of medicines in the country. That is a defensible policy position. It also means that the guideline recommendation and the available PBS pathway do not always align neatly, and many patients who would benefit from these medicines cannot access them at subsidised cost.

What can be discussed and what cannot

The handbook update is evidence-based and clinically appropriate. It is also general population guidance. Individual treatment decisions — whether to prescribe a GLP-1 RA, which one, at what dose — depend on co-morbidities, kidney function, cardiovascular history, individual risk profile, and the ongoing cost conversation.

That conversation is the one to have with your GP. Not Google. Not the TikTok doctor. Not the supplement stack that arrived with a comparison to Ozempic.

2 cents

If you or someone you care for has had a T2D diagnosis for more than a couple of years and the treatment plan hasn’t been reviewed recently, that is a reasonable prompt for a general practice appointment. The question to ask is whether the current medicines are still the best fit given the updated evidence — particularly if there is any cardiovascular disease, heart failure, or kidney disease in the picture.

If cost is the issue — and it is for many people — the cost conversation with your GP is a legitimate one. What’s PBS-subsidised, what isn’t, and what the clinical priority order should be given individual circumstances.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

The RACGP type 2 diabetes handbook refresh formally elevates GLP-1 receptor agonists and SGLT2 inhibitors based on their cardiorenal outcomes evidence, not just their glucose-lowering properties. The update reflects the strongest current evidence and gives GPs clearer guidance for patients at the higher end of cardiovascular and renal risk. The PBS access picture remains a work in progress — but the clinical standard has moved, and that matters for the conversation happening in general practice.